Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-05-12
2010-06-15
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S006400
Reexamination Certificate
active
07737123
ABSTRACT:
Daunorubicin (“DNR”) compounds synthesized with uncommon sugars exhibit enhanced effectiveness in treating various drug-resistant cancers.
REFERENCES:
patent: 5532218 (1996-07-01), Bargiotti et al.
patent: 6653289 (2003-11-01), Animati et al.
patent: 6673907 (2004-01-01), Priebe et al.
The Ohio State Univ. Research FNDN., Appln. No. PCT/US06/18630, filed May 12, 2006, International Search Report, Sep. 15, 2006.
Alper et al., “Metal Catalyzed Diazo Transfer for the Synthesis of Azides from Amines”, Tetrahedron Letters, vol. 37, No. 34, pp. 6029-6032, 1996.
Arcamone et al., “Configurational Requirements of the Sugar Moiety for the Pharmacological Activity of Anthracycline Disaccharides”, Biochemical Pharmacology vol. 57, pp. 1133-1139, 1999.
Caponigro et al., “A phase II study of sabarubicin (MEN-10755) as second line therap in patients with locally advanced or metasttic platinum/taxane resistant ovarian cancer”, Investigational New Drugs, 23: 85-89, 2005.
Champoux, J.J., “DNA Topoisomerases: Structure, Function, and Mechanism”, Annu. Rev. Biochem, 70: 369-413, 2001.
Ciesielska et al., “Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety”, Cell Biology and Toxicology, 21: pp. 139-147, 2005.
Gewirtz, D.A., “A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin”, Biochemical Pharmacology, vol. 57, pp. 727-741, 1999.
Lear, et al., “A Direct and efficient a-selective glycosylation protocol for the kedarcidin sugar, L-mycarose: AgPF6 as a remarkable activator activator of 2-deoxythioglycosides” Angew. Chem, Int. Ed, 40, No. 5, pp. 946-949, 2001.
Minotti et al., “Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity”, Pharmacological Reviews. vol. 56, No. 2, pp. 185-229, 2004.
Nadas et al., “Anthracyclines as effective anticancer drugs”, Expert Opin. Drug Ciscov. 1 (6), pp. 1-20.
Perez-Balderas et al., “Multivalent Neoglycoconjugates by Regiospecific cycloaddition of alkynes and azides using organic-soluble copper catalysts” Organic Letters, vol. 5, No. 11, pp. 1951-1954, 2003.
Portugal et al., “A new bisintercalating anthracycline with picomolar DNA binding affinity”, J Med Chem, 48, pp. 8209-8219, 2005.
Fang et al., “Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-Mediated drug resistance”, J Med Chem 49, 932-941, 2006.
Zhang et al., “Synthesis and biological activity of bisdaunorubicins”, Bioorganic & Medicinal Chemistry, 14, 426-434, 2006.
Fang Lanyan
Sun Duxin
Wang Peng George
Zhang Guisheng
Calfee Halter & Griswold LLP
Peselev Elli
The Ohio State University Research Foundation
LandOfFree
Multidrug resistant anticancer anthracyclines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multidrug resistant anticancer anthracyclines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multidrug resistant anticancer anthracyclines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237260